medigraphic.com
Órgano oficial de la Sociedad Mexicana de Cirugía Dermatológica y Oncológica, AC

2021, Number 3

<< Back Next >>

Dermatología Cosmética, Médica y Quirúrgica 2021; 19 (3)

Onichomycosis in diabetics: relevance of complication, treatment and prevention

Segundo-López LD, Sierra-Maeda KY, Arenas R

Language: Spanish
References: 31
Page: 289-295
PDF size: 133.62 Kb.


ABSTRACT

Onychomycosis is the most common fungal nail infection, caused by dermatophytes, yeasts and non-dermatophyte filamentous fungi. The risk factors identified for its development are: age, male gender, nail trauma, use of tight footwear, sports practices such as swimming, taking showers in public bathrooms, among others. Despite being seen as an aesthetic condition, it should not be unnoticed, especially in vulnerable groups, such as patients with diabetes mellitus, in whom it should be considered a public health issue, due to its high prevalence, difficulty in management, poor therapeutic adherence and high rates of recurrence; it might cause a significant social and financial impact on the public health. An early diagnosis and treatment of onychomycosis in this group would reduce the incidence of complications such as nail dystrophy, foot ulcers, osteomyelitis, and limb amputation.
The objective of this article is to recognize the importance of onychomycosis as a causal entity of morbidity in patients with diabetes and to recommend educational preventive strategies for patients in order to reduce complications and improve quality of life.


REFERENCES

  1. Care D, Standards of medical care in diabetes-2020, Diabetes Care 2020; 43:s1-2.

  2. Imbert JL, G. Gómez, Escudero RB et al., Onicomicosis por levaduras no comunes en diabéticos de un centro de salud, Semergen 2016; 42(7): 449-57.

  3. Rojas-Martínez R, Basto-Abreu A, Aguilar-Salinas CA et al., Prevalencia de diabetes por diagnóstico médico previo en México”, Salud Pública Mex 2018; 60(3).

  4. Instituto Nacional de Salud, Encuesta Nacional de Salud y Nutrición 2018-19. Resultados nacionales, Journal of Chemical Information and Modeling 2018; 53:1689-99.

  5. Saeedi P, Petersohn I, Salpea P et al., Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: results from the International Diabetes Federation Diabetes Atlas, Diabetes Res Clin Pract 2019; 157.

  6. Williams R, Karuranga S, Malanda B et al., Global and regional estimates and projections of diabetes-related health expenditure: results from the International Diabetes Federation Diabetes Atlas, 9ª ed., 2020.

  7. Rich P, Onychomycosis and tinea pedis in patients with diabetes, J Am Acad Dermatol 2000; 43:s130-4.

  8. Lladó DC, Arias LF, Mendoza IA et al., Onychomycosis and its influence on quality of life, Dermatología cmq 2016; 14(4):318-27.

  9. Mayser P, Freund V y Budihardja D, Toenail onychomycosis in diabetic patients: issues and management, Am J Clin Dermatol 2009; 10(4): 211-20.

  10. Bild DE, Selby JV, Sinnock P et al., Lower-extremity amputation in people with diabetes. Epidemiology and prevention, Diabetes Care 1989; 12(1):24-31.

  11. Elbendary A, El Tawdy A, Zaki N et al., Subclinical onychomycosis in patients with type ii diabetes, Dermatology Reports 2015; 7(3):34-5.

  12. Oz Y, Qoraan I, Oz A y Balta I, Prevalence and epidemiology of tinea pedis and toenail onychomycosis and antifungal susceptibility of the causative agents in patients with type 2 diabetes in Turkey, Int J Dermatol 2017; 56(1):68-74.

  13. Vanhooteghem O, Szepetiuk G, Paurobally D et al., Chronic interdigital dermatophytic infection: a common lesion associated with potentially severe consequences, Diabetes Res Clin Pract 2011; 91(1):23-5.

  14. Rossaneis MA, Haddad MDC, Mantovani MDF et al., Foot ulceration in patients with diabetes: a risk analysis, British Journal of Nursing 2017; 26(6):s6-14.

  15. Pesquera González C, Monofilamento de Semmes-Weinstein, Diabetes práctica actual y habilidades en atención primaria, 2011, pp. 8-14.

  16. Okano J, Kojima H, Katagi M et al., Hyperglycemia induces skin barrier dysfunctions with impairment of epidermal integrity in non-wounded skin of type 1 diabetic mice, plos One 2016; 11(11):1-22.

  17. Park HY, Kim JH, Jung M et al., A long-standing hyperglycaemic condition impairs skin barrier by accelerating skin ageing process, Exp Dermatol 2011; 20(12):969-74.

  18. Arenas R y Torres E, Micología médica ilustrada, 6ª ed., México, Mcgraw- Hill, 2019, p. 83.

  19. Torres GE, Landgrave I, Fernández R et al., Métodos diagnósticos en onicomicosis. Del koh a la biología molecular, Dermatología cmq 2010; 8(1): 39-46.

  20. McAuley WJ, Jones SA, Traynor MJ et al., An investigation of how fungal infection influences drug penetration through onychomycosis patient’s nail plates, Eur J Pharm Biopharm 2016; 102:178-84.

  21. Christenson JK, Peterson GM, Naunton M et al., Challenges and opportunities in the management of onychomycosis, J Fungi 2018; 4(3).

  22. Shofler D, Hamedani E, Seun J et al., Efficacy and safety of efinaconazole 10% solution in the treatment of onychomycosis in diabetic patients, Clin Podiatr Med Surg 2020; 37(2):401-7.

  23. Nijenhuis-Rosien L, Kleefstra N, Wolfhagen MJ et al., Laser therapy for onychomycosis in patients with diabetes at risk for foot complications: study protocol for a randomized, double-blind, controlled trial (laser-1), Trials 2015; 16(1): 24-6.

  24. Rodríguez Zendejas NJ, Fernández RF, Ávila RA et al., Tratamiento láser en onicomicosis, Dermatología cmq 2014; 12(1):7-12.

  25. Embil JM, Albalawi Z, Bowering K et al., Foot care, Can J Diabetes 2018; 42:s222-7.

  26. Akkus G, Evran M, Gungor D et al., Tinea pedis and onychomycosis frequency in diabetes mellitus patients and diabetic foot ulcers: a cross sectional-observational study, Pakistan J Med Sci 2016; 32(4): 891-5.

  27. James K, Orkaby AR y Schwartz AW, Foot examination for older adults, Am J Med 2020; 134(1):30-5.

  28. Crespo Erchiga V, Cómo prevenir las onicomicosis, Más Dermatología 2008; 4:21-4.

  29. Shemer A et al., Topical antifungal treatment prevents recurrence of toenail onychomycosis following cure, Dermatologic therapy 2017; 30(5):e12545.

  30. Sigurgeirsson B et al., Efficacy of amorolfine nail lacquer for the prophylaxis of onychomycosis over 3 years, Journal of the European Academy of Dermatology and Venereology 2010; 24(8):910-5.

  31. Cobos LD, Fierro AL, Arellano MI et al., La onicomicosis y su influencia en la calidad de vida, Dermatología cmq 2016; 14(4):318-27.




2020     |     www.medigraphic.com